Marksans Pharma Limited
MARKSANS.NS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$140.17B
Close$
$208.62
33.8% downside
Current Fair Value
33.8% downsideOvervalued by 33.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $140.17 Billion |
|---|---|
| Enterprise Value | - |
| Annual dividend | $0.90 |
| Dividend yield | 0.29% |
| Earnings per Share | $9.22 |
| Beta | 1.15 |
| Outstanding Shares | 453,163,746 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 27.06 |
|---|---|
| PEG | 15.96 |
| Price to Sales | 4.57 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$3.33
Consensus analyst estimateRevenue Estimate
$8.50 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$3.47
Consensus analyst estimateRevenue Estimate
$8.86 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Marksans Pharma Limited
1,685 employees
CEO: Mark Saldanha
Marksans Pharma Limited, along with its associated entities, operates globally in the pharmaceutical sector, focusing on the entire lifecycle of generic medications, from their initial research and development to manufacturing, marketing...